JISI YINGDA

jisi-yingda-logo

Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development.

#SimilarOrganizations #People #Financial #Website #More

JISI YINGDA

Industry:
Biopharma Biotechnology Pharmaceutical

Founded:
2010-11-01

Address:
Shanghai, Shanghai, China

Country:
China

Website Url:
http://www.jsinnopharm.com

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
14.1 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apache Mobile Non Scaleable Content DigiCert SSL Encryption Everywhere Alibaba HiChina DNS Alibaba Cloud MailBox


Similar Organizations

inventisbio-logo

InventisBio

InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.

vaxcell-bio-therapeutics-logo

Vaxcell Bio Therapeutics

Vaxcell Bio Therapeutics is an pharmaceutical firm that develops anti-cancer drugs, cellular drugs, immune drugs, and other medicines.

Current Employees Featured

not_available_image

Jintao Zhang
Jintao Zhang Founder & CEO @ Jisi Yingda
Founder & CEO
2010-11-01

Founder


not_available_image

Jintao Zhang

Investors List

ming-bioventures_image

Ming Bioventures

Ming Bioventures investment in Series B - Jisi Yingda

yifeng-capital_image

Yifeng Capital

Yifeng Capital investment in Series B - Jisi Yingda

baidu-ventures_image

Baidu Ventures

Baidu Ventures investment in Series B - Jisi Yingda

shenzhen-qianhai-beizeng-asset-management_image

Shenzhen Qianhai Beizeng Asset Management

Shenzhen Qianhai Beizeng Asset Management investment in Series B - Jisi Yingda

hangzhou-tigermed-technology-co-ltd_image

Tigermed

Tigermed investment in Series B - Jisi Yingda

jiuyou-capital_image

Jiuyou Capital

Jiuyou Capital investment in Series B - Jisi Yingda

zhidao-capital_image

Zhidao Capital

Zhidao Capital investment in Series A - Jisi Yingda

yifeng-capital_image

Yifeng Capital

Yifeng Capital investment in Series A - Jisi Yingda

oriental-fortune-capital_image

Oriental Fortune Capital

Oriental Fortune Capital investment in Series A - Jisi Yingda

suzhou-international-development-venture-capital_image

Suzhou International Development Venture Capital

Suzhou International Development Venture Capital investment in Series A - Jisi Yingda

Official Site Inspections

http://www.jsinnopharm.com

  • Host name: 47.111.134.89
  • IP address: 47.111.134.89
  • Location: Hangzhou China
  • Latitude: 30.294
  • Longitude: 120.1619
  • Timezone: Asia/Shanghai

Loading ...

More informations about "Jisi Yingda"

Jsinnopharm

[email protected]. Room 203 Building 1, No 1199 Landian Road, Pudong District, Shanghai, China. Room 602 Building B2, No 218 Xinghu Street, BioBAY, Suzhou Industrial Park, Suzhou, ChinaSee details»

About Us_JSI - jsinnopharm.com

[email protected]. Room 203 Building 1, No 1199 Landian Road, Pudong District, Shanghai, China. Room 602 Building B2, No 218 Xinghu Street, BioBAY, Suzhou Industrial …See details»

捷思英达医药

捷思英达医药技术有限公司是一家临床阶段的小分子抗癌新药研发企业。公司在上海张江拥有包括新药设计和药物化学、动物房、细胞房和生物分析等实验室,在美国有子公司负责美国临床开发。See details»

Jisi Yingda - Crunchbase Company Profile & Funding

Organization. Jisi Yingda . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Jisi Yingda …See details»

JS Innopharm - VentureRadar

"JS InnoPharm is a clinical stage biopharmaceutical company, dedicated to the discovery and development of novel chemical entities for cancer therapy, leveraging cutting edge knowledge …See details»

JS Innopharm | VentureRadar

Website: http://www.jsinnopharm.com/ Focuses on research and development of small molecule anticancer drugs with advanced facilities, and has multiple clinical and ...See details»

JS InnoPharm (Shanghai) Co., Ltd. - Drug pipelines, Patents

Www.jsinnopharm.com. Last update 23 Jan 2025. Overview. Pipeline. Deal. Translational Medicine. Profit. Grant & Funding(NIH) Investment. Financing. Overview. Tags. ... The …See details»

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

了解Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. (捷思英达医药技术(苏州)有限公司)公司的药物管线,治疗领域,技术平台,以及它的1项临床试, 6篇新闻,疾病领域:肿 …See details»

JS InnoPharm (Shanghai) Co., Ltd. - synapse.zhihuiya.com

了解JS InnoPharm (Shanghai) Co., Ltd. (捷思英达医药技术(上海)有限公司)公司的药物管线,治疗领域,技术平台,以及它的4项临床试验, 81篇新闻和5篇文献,疾病领域:免疫系统疾 …See details»

Jsinnopharm - Overview - aiHit

Jsinnopharm Overview - JS InnoPharm is a clinical stage biotech company focused on discovery and development of innovative small molecule oncology..See details»

捷思英达医药技术(上海)有限公司 - 爱企查

爱企查为您提供捷思英达医药技术(上海)有限公司的企业信息查询服务,查询捷思英达医药技术(上海)有限公司工商注册信息、电话邮箱、公司地址、经营风险、控股持股、发展动态、财 …See details»

公司概况_捷思英达 - jsinnopharm.com

[email protected]. 上海市浦东新区蓝靛路1199号1幢203室. 苏州工业园区星湖街218号生物医药产业园B2楼602单元See details»

JS InnoPharm 2025 Company Profile: Valuation, Funding

JS InnoPharm General Information Description. Provider of outsourcing services intended to research and develop new drugs. The company provides new drug discovery services …See details»

JS Innopharm Inc. Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for JS Innopharm Inc. of Naperville, IL. Get the latest business insights from Dun & Bradstreet.See details»

JS Innopharm - VentureRadar

Similar Companies: Scorpion Therapeutics USA Privately Held At Scorpion Therapeutics, we are working to expand the reach of precision medicine to more people with cancer, including …See details»

JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK ...

Jan 3, 2023 CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients …See details»

News Center_JSI - jsinnopharm.com

E-Mail:[email protected]. Home; About Us. Management Team; Pipeline; Investors; News Center; Join Us; Contact Us; News Center. News Center . News Center. Home > News …See details»

JS InnoPharm Announces First Patient Dosed with JSI ... - Business …

Jul 9, 2020 CHICAGO & SHANGHAI--(BUSINESS WIRE)--JS InnoPharm Ltd today announced the enrollment of the first patient in a Phase 1, open-label, monotherapy dose-escalation and …See details»

研发管线_捷思英达 - jsinnopharm.com

[email protected]. 上海市浦东新区蓝靛路1199号1幢203室. 苏州工业园区星湖街218号生物医药产业园B2楼602单元See details»

Pipeline_JSI - jsinnopharm.com

[email protected]. Room 203 Building 1, No 1199 Landian Road, Pudong District, Shanghai, China. Room 602 Building B2, No 218 Xinghu Street, BioBAY, Suzhou Industrial …See details»

linkstock.net © 2022. All rights reserved